<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03266783</url>
  </required_header>
  <id_info>
    <org_study_id>COBRRA</org_study_id>
    <nct_id>NCT03266783</nct_id>
  </id_info>
  <brief_title>Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous Thromboembolism</brief_title>
  <acronym>COBRRA</acronym>
  <official_title>Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous Thromboembolism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ottawa Hospital Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Canadian Venous Thromboembolism Clinical Trials and Outcomes Research (CanVECTOR) Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ottawa Hospital Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Apixaban and rivaroxaban have been compared to standard therapy for treatment of acute&#xD;
      symptomatic venous thromboembolism (VTE) in randomized controlled trials (RCTs), and are both&#xD;
      approved by Health Canada. No safety or efficacy data is available from direct head-to-head&#xD;
      comparison of these two anticoagulants. Lawsuits in the United States over bleeding events,&#xD;
      patient perceptions, and concerns with medication adherence are additional factors&#xD;
      highlighting the importance of a comparison trial. This multi-center, pragmatic, prospective,&#xD;
      randomized, open-label, blinded end-point (PROBE) trial aims to compare the safety of&#xD;
      apixaban and rivaroxaban for the treatment of VTE.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      VTE is the third leading cause of mortality by cardiovascular disease. Standard treatment for&#xD;
      acute VTE uses a combination of parenteral Low-Molecular-Weight Heparin (LMWH) and oral&#xD;
      vitamin K antagonists (VKA) for 3 months, and carries significant bleeding risk. The major&#xD;
      and/or clinically-relevant non-major bleeding (CRNMB) event rate is reported between 8.1-9.7%&#xD;
      during initial treatment. This treatment is burdensome owing to subcutaneous injections, drug&#xD;
      interactions, and laboratory monitoring. Direct oral anticoagulants (DOACs) are simpler to&#xD;
      use and do not require laboratory monitoring.&#xD;
&#xD;
      Rivaroxaban and apixaban are two DOACs targeting Factor Xa. Each DOAC was separately proven&#xD;
      effective and safe when compared to standard treatment. Comparison of the bleeding rates&#xD;
      between studies would favour use of apixaban over rivaroxaban; however, trial limitations and&#xD;
      lack of direct comparison between these two agents makes it impossible to draw firm&#xD;
      conclusions. This represents a dilemma in clinical practice because the absence of convincing&#xD;
      differences in safety has led to genuine uncertainty about which DOAC has the best&#xD;
      risk-to-benefit ratio.&#xD;
&#xD;
      To address these limitations, a head-to-head randomized controlled trial (RCT) is needed to&#xD;
      determine the safety (i.e. bleeding risk) of twice daily apixaban over once daily rivaroxaban&#xD;
      during the first 3 months of acute VTE treatment. Eligibility criteria will be less stringent&#xD;
      than the COBRRA pilot study and reflect real-world patients. Cost-effective analysis of&#xD;
      apixaban twice daily compared to rivaroxaban once daily will also be performed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 13, 2017</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The rate of adjudicated clinically relevant bleeding (CRB) events</measure>
    <time_frame>For the duration of the study: 3 months</time_frame>
    <description>CRB events are defined as the composite of major bleeding (MB) events and clinically relevant non-major bleeding (CRNMB) events.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adjudicated Major Bleeding events</measure>
    <time_frame>For the duration of the study: 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjudicated Clinically Relevant Non-Major Bleeding events</measure>
    <time_frame>For the duration of the study: 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjudicated recurrent VTE events</measure>
    <time_frame>For the duration of the study: 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjudicated VTE-related deaths</measure>
    <time_frame>For the duration of the study: 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>For the duration of the study: 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medication adherence</measure>
    <time_frame>For the duration of the study: 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality-adjusted life years (QALYs) gained</measure>
    <time_frame>For the duration of the study: 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incremental cost-effectiveness ratio</measure>
    <time_frame>For the duration of the study: 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of verbal consent on patient participation in comparison with participants from sites using written informed consent</measure>
    <time_frame>For the duration of the study: 3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2760</enrollment>
  <condition>Venous Thromboembolism</condition>
  <arm_group>
    <arm_group_label>Apixaban group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10 mg PO BID for 1 week, then 5 mg PO BID for 3 months of treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rivaroxaban group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>15 mg PO BID for 3 weeks, then 20 mg PO OD for 3 months of treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apixaban</intervention_name>
    <description>Refer to Apixaban group</description>
    <arm_group_label>Apixaban group</arm_group_label>
    <other_name>Eliquis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban</intervention_name>
    <description>Refer to Rivaroxaban group</description>
    <arm_group_label>Rivaroxaban group</arm_group_label>
    <other_name>Xarelto</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmed newly diagnosed symptomatic acute VTE (proximal power extremity DVT or&#xD;
             segmental or greater PE)&#xD;
&#xD;
          -  Age â‰¥ 18 years old&#xD;
&#xD;
          -  Informed consent obtained&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have received &gt; 72 hours of therapeutic anticoagulation&#xD;
&#xD;
          -  Creatinine clearance &lt; 30 ml/min calculated with the Cockcroft-Gault formula&#xD;
&#xD;
          -  Any contraindication for anticoagulation with apixaban or rivaroxaban as determined by&#xD;
             the treating physician such as, but not limited to:&#xD;
&#xD;
               -  active bleeding,&#xD;
&#xD;
               -  active malignancy, defined as a) diagnosed with cancer within the past 6 months;&#xD;
                  or b) recurrent, regionally advanced or metastatic disease; or c) currently&#xD;
                  receiving treatment or have received any treatment for cancer during the 6 months&#xD;
                  prior to randomization; or d) a hematologic malignancy not in complete remission,&#xD;
&#xD;
               -  weight &gt; 120 kg,&#xD;
&#xD;
               -  liver disease (Child-Pugh Class B or C),&#xD;
&#xD;
               -  use of contraindicated medications&#xD;
&#xD;
               -  another indication for long-term anticoagulation (e.g. atrial fibrillation)&#xD;
&#xD;
               -  pregnant (note below) or breastfeeding (Note: as reported by the patient or a&#xD;
                  pregnancy test will be ordered at the discretion of the treating physician for&#xD;
                  women of childbearing potential as per standard of care)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lana Castellucci, MD, FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ottawa Hospital Research Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lana Castellucci, MD, FRCPC</last_name>
    <phone>613-737-8899</phone>
    <phone_ext>74641</phone_ext>
    <email>lcastellucci@toh.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Madeleine Hill</last_name>
    <phone>613-737-8899</phone>
    <phone_ext>71067</phone_ext>
    <email>madhill@ohri.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deepa Suryanarayan, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Alberta Health Sciences</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cynthia Wu, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Paul's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tony Wan, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>QEII Health Science Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 2Y9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sudeep Shivakumar, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hamilton General Hospital</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kerstin de Wit, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Juravinski Hospital</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kerstin de Wit, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Healthcare Hamilton</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Douketis, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kingston General Hospital</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kerstin de Wit, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Center</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5W9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Kovacs, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital - General Campus</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lana Castellucci, MD, FRCPC</last_name>
      <phone>613-737-8899</phone>
      <phone_ext>74641</phone_ext>
      <email>lcastellucci@toh.ca</email>
    </contact>
    <contact_backup>
      <last_name>Limmy Lobo, MSc</last_name>
      <phone>613-737-8899</phone>
      <phone_ext>72103</phone_ext>
      <email>llobo@ohri.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Lana Castellucci, MD, FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UHN - Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erik Yeo, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>HÃ´pital SacrÃ©-Coeur de MontrÃ©al</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle Chagnon, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Mary's Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital</name>
      <address>
        <city>MontrÃ©al</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Kahn, MD, FRCPC</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>McGill University Health Center</name>
      <address>
        <city>MontrÃ©al</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Solymoss, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de QuÃ©bec-UniversitÃ© Laval</name>
      <address>
        <city>Quebec city</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benoit Cote, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Sherbrooke</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>GeneviÃ¨ve Le Templier, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 10, 2017</study_first_submitted>
  <study_first_submitted_qc>August 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 30, 2017</study_first_posted>
  <last_update_submitted>October 31, 2021</last_update_submitted>
  <last_update_submitted_qc>October 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rivaroxaban</mesh_term>
    <mesh_term>Apixaban</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

